NCT01190761View on ClinicalTrials.gov

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Healthy
Interventions
DRUG

Galantamine 4 mg Tablet, single dose

A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions

DRUG

Reminyl 4 mg Tablet, single dose

B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions

Trial Locations (1)

G 1 V 2K8

SFBC Anapharm, Sainte-Foy

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY